In clinical trials among patients with CRC, combined inhibition of TGF-β and PD-1/PD-L1 signaling caused multiple adverse effects, including pneumonitis, nausea, pruritus, rash, adrenal insufficiency, and hepatic impair (56–58). Here, TGFB1 is linked to pneumonitis.